(Q44031150)

29 November 2017

title

Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients (English)

1 reference

29 November 2017

1 reference

Caravaca F

1

1 reference

29 November 2017

Pizarro JL

2

1 reference

29 November 2017

Arrobas M

3

1 reference

29 November 2017

Cubero JJ

4

1 reference

29 November 2017

García MC

5

1 reference

29 November 2017

Perez-Miranda M

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 March 1994

1 reference

29 November 2017

1 reference

29 November 2017

volume

45

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

845-851

1 reference

USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Blood pressure changes during treatment with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Erythropoietin-associated hypertension: what role for blood viscosity changes?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Recombinant human erythropoietin for patients with AIDS treated with zidovudine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Erythropoietin treatment of anemia associated with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Hypertension following erythropoietin therapy in anemic hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Decreased blood pressure after a year of erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Recombinant human erythropoietin: 18 months' experience in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Treatment of the anemia of progressive renal failure with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Ticlopidine prevents renal disease progression in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Recombinant human erythropoietin treatment improves platelet function in uremic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Prothrombotic effect of erythropoietin in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Endothelin Release and Shift in Prostaglandin Balance Are Involved in the Modulation of Vascular Tone by Recombinant Erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1994.111

7 January 2021

Identifiers

DOI

10.1038/KI.1994.111

1 reference

29 November 2017

1 reference